J G OLeary
Overview
Explore the profile of J G OLeary including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
404
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhutta A, Garcia-Tsao G, Reddy K, Tandon P, Wong F, OLeary J, et al.
Aliment Pharmacol Ther
. 2017 Oct;
47(1):78-85.
PMID: 28994122
Background: It has been suggested that beta-blockers may increase mortality in patients with cirrhosis and refractory ascites but the effect of beta-blockers discontinuation or reinitiation has not been examined. Aims:...
2.
3.
Wong F, OLeary J, Reddy K, Garcia-Tsao G, Fallon M, Biggins S, et al.
Am J Gastroenterol
. 2017 Apr;
112(7):1103-1110.
PMID: 28440305
Objectives: The International Ascites Club (IAC) recently defined Stage 1 acute kidney injury (AKI) for cirrhosis as an acute increase in serum creatinine (SCr) by ≥0.3 mg/dl or by ≥50%...
4.
OLeary J, Levitsky J, Wong F, Nadim M, Charlton M, Kim W
Am J Transplant
. 2016 Mar;
16(9):2516-31.
PMID: 26990924
Acute kidney injury (AKI) and chronic kidney disease (CKD) are common in patients awaiting liver transplantation, and both have a marked impact on the perioperative and long-term morbidity and mortality...
5.
Levitsky J, OLeary J, Asrani S, Sharma P, Fung J, Wiseman A, et al.
Am J Transplant
. 2016 Mar;
16(9):2532-44.
PMID: 26932352
Both acute and chronic kidney disease are common after liver transplantation and result in significant morbidity and mortality. The introduction of the Model for End-stage Liver Disease score has directly...
6.
OLeary J, Cai J, Freeman R, Banuelos N, Hart B, Johnson M, et al.
Am J Transplant
. 2015 Oct;
16(2):603-14.
PMID: 26469278
Donor-specific alloantibodies (DSA) can cause acute antibody-mediated rejection (AMR) in all solid organ allografts. However, long-term outcome in patients with posttransplant DSA needs further study. We retrospectively evaluated prospectively collected...
7.
OLeary J, Kaneku H, Banuelos N, Jennings L, Klintmalm G, Terasaki P
Am J Transplant
. 2015 Mar;
15(4):1003-13.
PMID: 25772599
Recent literature confirms donor-specific HLA alloantibodies (DSA) impair 5-year survival in some but not all liver transplant recipients. In an effort to improve DSA testing's association with rejection and death,...
8.
9.
OLeary J, Demetris A, Friedman L, Gebel H, Halloran P, Kirk A, et al.
Am J Transplant
. 2014 Mar;
14(4):779-87.
PMID: 24580828
The impact of donor-specific HLA alloantibodies (DSA) on short- and long-term liver transplant outcome is not clearly defined. While it is clear that not all levels of allosensitization produce overt...
10.
Kaneku H, OLeary J, Banuelos N, Jennings L, Susskind B, Klintmalm G, et al.
Am J Transplant
. 2013 Jun;
13(6):1541-8.
PMID: 23721554
The role of de novo donor-specific HLA antibodies (DSA) in liver transplantation remains unknown as most of the previous studies have only focused on preformed HLA antibodies. To understand the...